Key Highlights
- ImmuPharma plc — LSE:IMM — gained 6.08% in the latest market snapshot.
- The move comes immediately after several significant company developments announced on 15 September 2026.
- ImmuPharma submitted an international Patent application covering its P140 precision-medicine approach for autoimmune diseases.
- New peer-reviewed research has reported biological effects of P140 in a preclinical model of metabolic dysfunction-associated steatohepatitis, or MASH.
- The company has also provided its latest half-year financial update and continues development of Kapiglucagon.
- A £6.47 million Equity fundraise completed in April 2026 is expected by the company to provide funding runway into the second half of 2028.
Why Is ImmuPharma LSE:IMM Up 6.08% Today?
ImmuPharma is back in focus after LSE:IMM gained 6.08%, with the latest move coming against a backdrop of several important scientific, intellectual-property and corporate developments.
The timing is notable because ImmuPharma released multiple updates on 15 September covering its P140 programme, new preclinical research and its six-month financial results.
For a small-cap biotechnology company, such developments can materially influence investor attention because the valuation is closely linked to the progress of its drug-development pipeline, intellectual-property position, potential commercial partnerships and funding capacity.
What Is Driving Investor Interest in P140?
P140 remains the central asset within ImmuPharma's development strategy. The company is developing the peptide across autoimmune and inflammatory diseases, with lupus historically being a major area of focus.
On 15 September, ImmuPharma announced an international patent filing covering its P140 precision-medicine approach, including the identification and treatment of patients exhibiting a particular immune profile. The development is relevant because precision medicine could potentially allow treatment strategies to be directed toward specific patient groups rather than applying the same approach across an entire disease population.
The patent development adds another layer to the P140 story by potentially strengthening the intellectual-property framework around the programme.
Could MASH Research Expand the P140 Opportunity?
Another important development is new peer-reviewed research examining P140 in a preclinical model of metabolic dysfunction-associated steatohepatitis, commonly known as MASH.
The research reported reductions in liver inflammation, steatohepatitis and fibrosis in the experimental model. The findings broaden the areas in which ImmuPharma's P140 platform is being investigated beyond its established autoimmune-disease focus.
However, the research is preclinical. Results from laboratory and animal models do not establish that the same effects will occur in humans, meaning further development and clinical validation remain important.
What Is Happening With Kapiglucagon?
Kapiglucagon represents another development programme being followed by investors.
During 2026, ImmuPharma moved the programme forward through Manufacturing and development partnerships. The company previously selected Bachem for production of Kapiglucagon active pharmaceutical ingredient and Thermo Fisher for contract development and manufacturing activities. A bioanalytical contract research organisation was also selected in August.
These developments indicate that the programme is progressing through its development infrastructure, although the ultimate commercial value will depend on clinical development, regulatory progress and future partnering.
What Did ImmuPharma Report in Its Latest Financial Results?
For the six months ended 30 June 2026, ImmuPharma reported an operating loss of approximately £1.1 million, compared with £1.2 million in the corresponding period of 2025.
Research and development expenditure declined to around £0.6 million, from £0.7 million previously, while administrative expenses remained around £0.4 million.
The reported loss for the period was approximately £4.7 million, compared with £1.9 million a year earlier. A major Factor was a £3.36 million fair-value finance loss associated with a derivative financial asset rather than a comparable increase in operating expenditure.
This distinction is important when assessing the latest numbers because the headline loss was affected significantly by a non-operating financial valuation item.
Has ImmuPharma Strengthened Its Funding Position?
Funding remains a key consideration for development-stage biotechnology companies.
ImmuPharma raised approximately £6.47 million through Equity Financing in April 2026. The company said the financing, together with existing resources, is expected to provide a cash runway into the second half of 2028. At 30 June, reported cash stood at approximately £0.7 million, alongside a derivative financial asset valued at around £2 million.
The funding runway is particularly relevant because it provides the company with greater visibility while its P140 and Kapiglucagon programmes continue through development.
At the same time, investors will continue monitoring expenditure, clinical-development requirements and whether additional Capital is eventually required.
How Has LSE:IMM Been Trading Recently?
ImmuPharma has experienced substantial Volatility during September. Historical market data shows the shares closing at 4.00p on 7 September, rising 11.11%, before reaching 4.10p on 8 September. The stock subsequently moved lower, closing at 3.50p on 14 September and 3.33p on 15 September.
Against that backdrop, the 6.08% move shown in the latest market snapshot represents a notable rebound in short-term trading activity.
The stock's relatively small Market Capitalisation and biotechnology exposure can contribute to significant daily percentage movements when new scientific or corporate information emerges.
What Should Investors Watch Next for ImmuPharma?
The main areas to monitor are further progress with the P140 precision-medicine programme, intellectual-property developments, potential commercial partnering discussions and clinical-development milestones.
For Kapiglucagon, manufacturing progress and the transition into active development remain important.
The company's funding position will also remain closely watched. While the April financing provides management with a stated runway into the second half of 2028, the future capital requirement will depend on development costs and the pace of its programmes.
What Are the Main Risks Around LSE:IMM?
The key risks include clinical-development uncertainty, regulatory requirements, funding requirements and the possibility that preclinical findings do not translate into successful human studies.
P140's commercial potential also depends on further clinical validation and potential partnerships. Kapiglucagon carries similar development and regulatory risks.
Consequently, the latest scientific announcements provide additional information about the company's pipeline but do not by themselves establish future commercial outcomes.






Please wait processing your request...